Ischemic Heart Disease Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceReduces triglycerides; anti-inflammatory; may reduce cardiovascular events
Supporting Studies (1)
Supports mitochondrial function; statin-depleted; may improve heart function
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsSupports cardiac rhythm; deficiency common; may reduce arrhythmias
Supporting Studies (1)
Deficiency associated with cardiovascular risk; may affect endothelial function
Supporting Studies (1)
Supports fatty acid metabolism; may improve cardiac function post-MI
Supporting Studies (1)
Lower homocysteine; mixed evidence for cardiovascular outcomes
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Ischemic heart disease (IHD), also called coronary artery disease (CAD), occurs when the heart's blood supply is reduced due to narrowing or blockage of the coronary arteries. It is the leading cause of death worldwide.
HOW IT DEVELOPS:
SYMPTOMS:
CRITICAL: IHD requires comprehensive medical management. This protocol is SUPPORTIVE ONLY.
GUIDELINE-DIRECTED THERAPY:
LIFESTYLE MODIFICATIONS (MOST IMPORTANT):
* Omega-3s (especially icosapent ethyl) have cardiovascular benefits.
* CoQ10 supports energy production in heart muscle.
* Magnesium supports cardiac rhythm.
Expected timeline: Lifestyle changes and medications reduce cardiovascular risk over months to years. Supplements provide additional modest support.
Clinical Perspective
Ischemic Heart Disease: Atherosclerotic coronary artery disease; leading cause of death globally. Presentations: stable angina, acute coronary syndrome (NSTEMI, STEMI), sudden cardiac death, ischemic cardiomyopathy. Risk factors: hyperlipidemia, hypertension, diabetes, smoking, family history, obesity.
CRITICAL: Guideline-directed medical therapy (GDMT) reduces mortality - aspirin, high-intensity statin, ACE-I/ARB if indicated. Risk factor modification essential. Omega-3 (icosapent ethyl 4g) reduces CV events in high-risk patients with elevated TG (REDUCE-IT). CoQ10 may help especially if on statin. Supplements adjunctive to proven therapies - don't substitute.
* Omega-3 Fatty Acids (A-grade): CV outcomes. Meta-analysis: (PMID: 27840029). 2-4g EPA+DHA daily. Icosapent ethyl FDA-approved.
* CoQ10 (B-grade): Cardiac function. Meta-analysis: (PMID: 24268541). 100-300mg daily.
* Magnesium (B-grade): Rhythm support. Meta-analysis: (PMID: 28445426). 300-400mg daily.
* Vitamin D (C-grade): Endothelial function. Systematic review: (PMID: 28750270). 2000-4000 IU daily.
* L-Carnitine (C-grade): Fatty acid metabolism. Meta-analysis: (PMID: 23597877). 2-3g daily.
* B Vitamins (C-grade): Homocysteine. Meta-analysis: (PMID: 27450775). Mixed outcomes data.
Assessment targets: LDL (<70 for very high risk), BP, A1c, symptoms, exercise capacity, echo if indicated.
Protocol notes: Statins: high-intensity (atorvastatin 40-80mg, rosuvastatin 20-40mg); target LDL <70 if very high risk, <55 for extreme risk. Aspirin: 81mg daily; balance bleeding risk. Icosapent ethyl: if TG 135-499 on statin with established CVD or diabetes + risk factors (REDUCE-IT). PCSK9 inhibitors: if LDL not at goal on max statin. Exercise: cardiac rehab post-MI/revascularization; ongoing regular activity. Smoking: most impactful modifiable risk; cessation counseling + pharmacotherapy. Mediterranean diet: evidence-based; PREDIMED trial. Cardiac rehab: improves outcomes; underutilized. Stress testing: for diagnosis and risk stratification. Revascularization: PCI for appropriate lesions; CABG for left main, 3-vessel disease with diabetes.